# Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease

> **NCT00357279** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 352 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** denufosol tetrasodium (INS37217) Inhalation Solution
- **DRUG:** Placebo - 0.9% w/v sodium chloride solution

## Key facts

- **NCT ID:** NCT00357279
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357279, "Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00357279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*